Status:
COMPLETED
Phase1, Single Dose, Crossover Study to Determine Bioequivalence
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
All Genders
21-55 years
Phase:
PHASE1
Brief Summary
The objective of this study is to demonstrate bioequivalence of 4 mg tablet of formulation D and formulation E(1).
Eligibility Criteria
Inclusion
- Healthy male or female Chinese or Japanese subjects
Exclusion
- Evidence or history of clinically significant findings at screening
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00786240
Start Date
January 1 2009
End Date
February 1 2009
Last Update
September 9 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Singapore, Singapore, Singapore, 188770